Olema Pharmaceuticals announced its plans to commence a public offering, subject to market and other conditions, to issue and sell shares of its common stock, or for certain investors that so choose, in lieu of shares of common stock, pre-funded warrants to purchase shares of its common stock. All of the securities are being offered by Olema. TD Cowen is acting as book-running manager for the proposed offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Pharmaceuticals Terminates ATM Prospectus
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Positive Outlook for Olema’s OPERA-02 Study Following Roche’s Successful Phase 3 Trial Results
- Positive Outlook on Olema Pharmaceuticals’ Palazestrant Driven by Promising Trial Data and Market Potential
- Olema Oncology price target raised to $36 from $28 at H.C. Wainwright